Less than a year after emerging from stealth, Tome Biosciences Inc. now plans to eliminate all the jobs at its Watertown facility — including the positions of its chief executive and chief scientific officers.
Tome debuted in December 2023 with quite the haul in venture capital funding: $213 million across Series A and B investment rounds. The company counted about 140 employees, at the end of last year, nearly all of whom were based at its labs in Watertown.
WATCH ANYTIME FOR FREE
 |
Stream NBC10 Boston news for free, 24/7, wherever you are. |
More on this story from Boston Business Journal
Get updates on what's happening in Boston to your inbox. Sign up for our News Headlines newsletter.
Copyright Boston Business Journal
